It is proved that oral TDNPs can reduce proinflammatory cytokines (TNF-α, IL-6 and IL-1β), upregulate antioxidant gene HO-1 to relieve colitis in mice and accelerate colitis regression. The gene discussed is IL1B; the disease is colitis.